In this issue we talk with …
… Ariad’s Harvey Berger and Timothy Clackson
Who discuss building a sustainable biotech business and following their own path
And we take a look at …
… Personalised cancer medicines
As our knowledge of the area improves the oncology and orphan drugs worlds are drawn ever closer …
… The science of decision making
Gaining an insight into the way people think can provide a major competitive advantage …
… Chinese healthcare reforms
The impact of tighter regulations and an emerging domestic industry on global pharma companies …
… Has Portugal fallen out of love with branded medicines
The deep recession and debt crisis has led to sustained growth in the country’s use of generics …
… Communicating value with patient adherence programmes
Delivering ‘beyond the pill’ to provide extra benefits for physicians, payers, patients and regulators …
Also with this issue …
… The megingococcal b research pipeline
The approval of the first vaccine in the form of Novartis’ Bexsero represents a major milestone
… Translational pharmacology
A masterclass on ways to boost clinical trial success rates
… Bioclusters
European pharma job cuts are releasing talent that’s driving the development of bioclusters …
and in addition …
… Early access and regulation in rare diseases
PME‘s next Orphan Drugs and Rare Diseases supplement tackles how to meet patient needs …
View PME September 2013 online
Register here to receive email notification of future digital editions of PME or contact the subscriptions department to enquire about receiving a print copy of the magazine. More PMLiVE digital editions can be found here.
PME is also available to download as an app for iPhone, iPad, Android and Kindle Fire
